Home / Business and Economy / Nautilus Biotech Pivots to Proteoforms, Sees Early Revenue
Nautilus Biotech Pivots to Proteoforms, Sees Early Revenue
29 Jul
Summary
- Proteoform application shows strong customer interest and commercial potential.
- First revenues recognized from collaborations with Baylor and MJF.
- Cash runway extends into Q1 2028, but additional fundraising may be needed.
Nautilus Biotechnology Inc. is prioritizing its proteoform application, a move met with significant customer excitement and perceived commercial value. This strategic pivot has already yielded initial revenue streams through collaborations with Baylor College and the Michael J. Fox Foundation.
The company boasts a healthy financial standing, with its cash runway projected to last until the first quarter of 2028. This financial stability supports the ongoing development of its unique proteoform assays, which offer unparalleled single-molecule resolution insights.
However, challenges persist. The broad-scale proteome application is experiencing delays, missing its targeted launch. Furthermore, the company reported a net loss of $14.5 million in the second quarter of 2026. To fuel proteoform expansion and market development, additional fundraising is anticipated between now and mid-2027, potentially impacting existing shareholders.
Nautilus's sales team is currently small, which may affect the pace of commercial scaling. Despite this, the CEO expressed confidence in the current team's efficiency, focusing on the unique proteoform capabilities to drive engagement and anticipates sales team expansion as the business grows.
